ProKidney Bolsters Commercial Strategy with Greg Madison as CCO
ByAinvest
Wednesday, Mar 25, 2026 4:03 pm ET1min read
PROK--
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to drive the company's commercial strategy for its potential cell therapy, rilparencel. Madison brings over two decades of executive leadership experience in biopharmaceutical companies and has a proven track record of building high-performing organizations and shaping commercial strategies. His appointment aims to position rilparencel for potential commercialization and address the unmet need for patients with advanced chronic kidney disease and diabetes.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet